Viatris Inc. (VTRS)
Is Viatris (VTRS) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Viatris Inc. (VTRS) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)
Viatris Inc. (NASDAQ:VTRS ) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 14, 2025 11:15 AM ET Company Participants Scott Smith - CEO Doretta Mistras - CFO Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Conference Call Participants Chris Schott - JPMorgan Doretta Mistras - CFO Chris Schott Good morning, everybody.
Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes
We have rated Viatris in the "neutral/hold" category since 2021. Over this time, the stock has lagged Treasury bills, despite sporting a high double digit "free cash flow yield". We tell you why that has not worked till now and why we are getting ready to trade this.
US FDA sends warning letter to Viatris over India manufacturing facility
Viatris said on Monday it has received a warning letter from the U.S. Food and Drug Administration after an inspection at its oral finished dose manufacturing facility in Indore, India earlier this year.
UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe
Britain's competition watchdog fined U.S. firm Viatris 1.5 million pounds ($1.88 million) on Friday for violating an order during its investigation into Theramex's acquisition of European rights to two of Viatris's women's healthcare product ranges.
Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript)
Viatris Inc. (NASDAQ:VTRS ) Jefferies London Healthcare Conference Transcript November 21, 2024 5:30 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Corinne Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo All right. Good morning, everybody.
Viatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript)
Viatris Inc. (NASDAQ:VTRS ) UBS Global Healthcare Conference November 12, 2024 11:45 AM ET Company Participants Doretta Mistras - CFO Conference Call Participants Ashwani Verma - UBS Ashwani Verma Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma at UBS, and welcome to UBS Global Healthcare Conference with us.
Bargain Priced Viatris Reports Strong Q3 Earnings Results
Bargain Priced Viatris Reports Strong Q3 Earnings Results
Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown
Viatris Inc. VTRS reported third-quarter 2024 total net sales of $3.74 billion. That's down 5%, beating the consensus of $3.71 billion, but up about 3% on a divestiture-adjusted operational basis compared to third-quarter 2023 results.
Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance
VTRS Q3 earnings and sales beat estimates. New products perform well.
Viatris Inc. (VTRS) Q3 2024 Earnings Call Transcript
Viatris Inc. (NASDAQ:VTRS ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants Glen Santangelo - Jefferies Jason Gerberry - Bank of America Ethan Brown - JPMorgan Ashwani Verma - UBS David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Good morning, everyone, and welcome to the Viatris Q3 2024 Earnings Call. All participants will be in a listen-only mode.
Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
